A Phase 1 interventional study of Regorafenib (Stivarga, BAY73-4506) in Neoplasms, sponsored by Bayer. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-20.
Sponsored by Bayer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 24 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:
For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:
Exclusion Criteria:
For subjects with SEVERELY IMPAIRED renal function:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
Drug: Regorafenib (Stivarga, BAY73-4506)
Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
Drug: Regorafenib (Stivarga, BAY73-4506)
Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. The AUC(0-tlast) \[Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point \>LLOQ (Lower Limit of Quantification)\] is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8
Amount of drug excreted into urine during the collection interval 0-24 hours post dose was expressed as percentage of administered dose.
Time frame: Days 1-2: 0-24 hours
AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUC(0-24) is defined as AUC divided from zero to 24 hours after single (first) dose.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose
Cmax (Maximum Drug Concentration in Plasma After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Tmax (Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Tlast (Time of Last Data Point >LLOQ) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
based on non-compartmental PK evaluation.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
t1/2 (Half-life Associated With the Terminal Slope) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. t1/2 refers to the elimination of the drug. It is the time taken for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. It is expressed in hours (h) and derived from the terminal slope of the concentration versus time curve.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
CL/F (Total Body Clearance of Drug After Extravascular Administration) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Vz/F (Apparent Volume of Distribution During Terminal Phase After Single (First) Oral Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
AUC(0-24)md ((AUC(0-24) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.
Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose
Cmax,md (Cmax After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
AUC(0-tlast)md (AUC(0-tlast) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
based on non-compartmental PK evaluation.
Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
based on non-compartmental PK evaluation
Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Tlast,md (Tlast After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
based on non-compartmental PK evaluation
Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
RACmax (Accumulation Ratio Calculated From Cmax,md and Cmax) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. Accumulation ratio based on maximum plasma concentration (Cmax) was calculated as ratio of Cmax,md and Cmax.
Time frame: Up to 25 days
RAAUC (Accumulation Ratio Calculated From AUC(0-24)md and AUC(0-24)) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. RAAUC calculated as ratio of AUC(0-24)md and AUC(0-24).
Time frame: Up to 25 days
RLin (Linearity Factor Calculated as Ratio From AUC(0-24)md and AUC) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Based on non-compartmental PK evaluation. RLin is the linearity factor of PK after multiple administrations of identical doses calculated as ratio of AUC(0-24)md and AUC.
Time frame: Up to 25 days
AE,ur(0-24)md (AE,ur(0-24) After Multiple-dose Administration) for Metabolites M-7 and M-8
based on non-compartmental PK evaluation
Time frame: Days 21-22: 0-24 hours
AE,ur(0-10) Stage 1 (Amount of Drug Excreted Via Urine During the Collection Interval 0-10 Hours Post Administration) for Metabolites M-7 and M-8
based on non-compartmental PK evaluation
Time frame: Days 1-2: 0-10 hours
AE,ur(10-24) Stage 1 ((Amount of Drug Excreted Via Urine During the Collection Interval 10-24 Hours Post Administration) for Metabolites M-7 and M-8
based on non-compartmental PK evaluation
Time frame: Days 1-2: 10-24 hours
AE,ur(0-10) Stage 2 for Metabolites M-7 and M-8
based on non-compartmental PK evaluation
Time frame: Days 21-22: 0-10 hours
AE,ur(10-24) Stage 2 for Metabolites M-7 and M-8
based on non-compartmental PK evaluation
Time frame: Days 21-22: 10-24 hours
Tumor Response Assessment for Measurable Lesions According to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)
Positron emission tomography - computed tomography (ET-CT), CT, or magnetic resonance imaging (MRI) scans of all anatomic regions involved with the disease were performed to assess tumor response using the Response Evaluation Criteria in Solid Tumors, Version 1.1. (RECIST v1.1). Bone metastases were assessed by bone scintigraphy (bone scan). Tumor measurements and evaluation of tumor response were performed at baseline and within the last 7 days of Cycle 2. Thereafter, if subjects continued regorafenib treatment, tumor assessments were performed after every third cycle and at the end-of-treatment (EOT) visit. In addition, outcome of "Assessment of Bone Metastases by Scintigraphy if Applicable (Bone Scan)" was registered, the results of which has been reported as tumor response in this outcome as well.
Time frame: Up to 6 months
Overall, 39 adult male or female participants with locally advanced and / or metastatic solid tumors were screened at 4 study centers in Canada and 4 study centers in the USA.
| Milestone | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Started | 18 | 6 |
| Received treatment | 18 | 6 |
| Completed | 0 | 0 |
| Not completed | 18 | 6 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Disease progression | 13 | 3 |
Based on non-compartmental PK evaluation. The AUC(0-tlast) \[Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point \>LLOQ (Lower Limit of Quantification)\] is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg*h/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 67.2 ± 45.5 | 76.6 ± 50.3 |
| Regorafenib metabolites M-2 | 27.8 ± 80.4 | 19.0 ± 58.7 |
| Regorafenib metabolites M-5 | 5.25 ± 145 | 2.34 ± 79.8 |
Amount of drug excreted into urine during the collection interval 0-24 hours post dose was expressed as percentage of administered dose.
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 3.607 ± 1.124 | 1.309 ± 0.649 |
| Regorafenib metabolites M-8 | 1.120 ± 0.737 | 0.184 ± 0.229 |
Based on non-compartmental PK evaluation. AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
| mg*h/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib (n=6, 3) | 59.5 ± 26.1 | 98.7 ± 71.0 |
| Regorafenib metabolites M-2 (n=13, 4) | 32.6 ± 89.0 | 20.8 ± 65.4 |
| Regorafenib metabolites M-5 (n=0, 0) | NA ± NA | NA ± NA |
Based on non-compartmental PK evaluation. The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUC(0-24) is defined as AUC divided from zero to 24 hours after single (first) dose.
| mg*h/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 30.0 ± 39.8 | 28.4 ± 62.0 |
| Regorafenib metabolites M-2 | 13.5 ± 70.0 | 7.93 ± 72.7 |
| Regorafenib metabolites M-5 | 1.17 ± 116 | 0.474 ± 101 |
Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 2.45 ± 47 | 2.00 ± 69.7 |
| Regorafenib metabolites M-2 | 1.01 ± 66.7 | 0.525 ± 69.6 |
| Regorafenib metabolites M-5 | 0.0877 ± 125 | 0.0341 ± 67.0 |
Based on non-compartmental PK evaluation.Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 4.03 (1.00 to 24.0) | 3.04 (1.00 to 23.75) |
| Regorafenib metabolites M-2 | 4.03 (1.00 to 24.0) | 6.04 (1.98 to 23.8) |
| Regorafenib metabolites M-5 | 47.8 (6.00 to 96.1) | 48.9 (24.1 to 95.8) |
based on non-compartmental PK evaluation.
| h | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 95.7 (46.4 to 96.3) | 95.8 (95.6 to 96.0) |
| Regorafenib metabolites M-2 | 95.7 (46.4 to 96.3) | 95.8 (95.6 to 96.0) |
| Regorafenib metabolites M-5 | 95.7 (46.4 to 96.3) | 95.8 (95.6 to 96.0) |
Based on non-compartmental PK evaluation. t1/2 refers to the elimination of the drug. It is the time taken for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. It is expressed in hours (h) and derived from the terminal slope of the concentration versus time curve.
| h | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib (n=6, 3) | 28.7 ± 23.0 | 27.9 ± 32.0 |
| Regorafenib metabolites M-2 (n=13, 4) | 26.2 ± 25.7 | 25.5 ± 24.0 |
| Regorafenib metabolites M-5 (n=0, 0) | NA ± NA | NA ± NA |
Based on non-compartmental PK evaluation.Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/H | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib (n=6, 3) | 2.69 ± 26.1 | 1.62 ± 71.0 |
| Regorafenib metabolites M-2 (n=13, 4) | 5.08 ± 89.0 | 7.95 ± 65.4 |
| Regorafenib metabolites M-5 (n=0, 0) | NA ± NA | NA ± NA |
Based on non-compartmental PK evaluation.Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib (n=6, 3) | 111 ± 31.9 | 65.2 ± 81.0 |
| Regorafenib metabolites M-2 (n=13, 4) | 192 ± 83.8 | 292 ± 71.1 |
| Regorafenib metabolites M-5 (n=0, 0) | NA ± NA | NA ± NA |
Based on non-compartmental PK evaluation.
| mg*h/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 56.0 ± 56.4 | 45.2 ± 45.8 |
| Regorafenib metabolites M-2 | 53.9 ± 63.1 | 35.0 ± 207 |
| Regorafenib metabolites M-5 | 49.7 ± 130 | 34.2 ± 438 |
Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 3.52 ± 54.9 | 2.87 ± 62.2 |
| Regorafenib metabolites M-2 | 3.52 ± 58.8 | 2.29 ± 257 |
| Regorafenib metabolites M-5 | 3.25 ± 133 | 2.23 ± 659 |
based on non-compartmental PK evaluation.
| mg*h/L | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 133 ± 55.1 | 111 ± 54.8 |
| Regorafenib metabolites M-2 | 136 ± 64.9 | 92.3 ± 280 |
| Regorafenib metabolites M-5 | 183 ± 128 | 134 ± 459 |
based on non-compartmental PK evaluation
| h | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 3.97 (0.000 to 23.8) | 4.25 (0.000 to 10.0) |
| Regorafenib metabolites M-2 | 4.12 (0.000 to 23.9) | 4.00 (0.000 to 10.0) |
| Regorafenib metabolites M-5 | 0.000 (0.000 to 24.0) | 0.000 (0.000 to 8.00) |
based on non-compartmental PK evaluation
| h | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 96.0 (48.1 to 96.5) | 95.3 (94.3 to 96.0) |
| Regorafenib metabolites M-2 | 96.0 (48.1 to 96.5) | 95.3 (94.3 to 96.0) |
| Regorafenib metabolites M-5 | 96.0 (48.1 to 96.5) | 95.3 (94.3 to 96.0) |
Based on non-compartmental PK evaluation. Accumulation ratio based on maximum plasma concentration (Cmax) was calculated as ratio of Cmax,md and Cmax.
| Accumulation Ratio | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 1.51 ± 60.0 | 1.96 ± 68.2 |
| Regorafenib metabolites M-2 | 3.83 ± 44.9 | 5.94 ± 216 |
| Regorafenib metabolites M-5 | 39.7 ± 94.0 | 81.8 ± 515 |
Based on non-compartmental PK evaluation. RAAUC calculated as ratio of AUC(0-24)md and AUC(0-24).
| Accumulation Ratio | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib | 1.97 ± 57.1 | 1.96 ± 52.0 |
| Regorafenib metabolites M-2 | 4.32 ± 45.0 | 6.00 ± 172 |
| Regorafenib metabolites M-5 | 48.3 ± 76.0 | 87.0 ± 585 |
Based on non-compartmental PK evaluation. RLin is the linearity factor of PK after multiple administrations of identical doses calculated as ratio of AUC(0-24)md and AUC.
| Linearity factor calculated as ratio | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib (n=5, 2) | 0.957 ± 49.2 | 0.469 ± 5.24 |
| Regorafenib metabolites M-2 (n= 9, 2) | 1.98 ± 40.7 | 1.19 ± 144 |
| Regorafenib metabolites M-5 (n=0, 0) | NA ± NA | NA ± NA |
based on non-compartmental PK evaluation
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 5.094 ± 2.322 | 1.647 ± 0.753 |
| Regorafenib metabolites M-8 | 2.566 ± 1.561 | 1.238 ± 0.684 |
based on non-compartmental PK evaluation
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 1.752 ± 0.611 | 0.449 ± 0.301 |
| Regorafenib metabolites M-8 | 0.486 ± 0.382 | 0.053 ± 0.089 |
based on non-compartmental PK evaluation
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 1.855 ± 0.629 | 0.746 ± 0.441 |
| Regorafenib metabolites M-8 | 0.634 ± 0.374 | 0.117 ± 0.133 |
based on non-compartmental PK evaluation
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 2.655 ± 1.346 | 0.600 ± 0.255 |
| Regorafenib metabolites M-8 | 1.292 ± 0.902 | 0.469 ± 0.338 |
based on non-compartmental PK evaluation
| percentage of dose | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Regorafenib metabolites M-7 | 2.440 ± 1.098 | 1.047 ± 0.738 |
| Regorafenib metabolites M-8 | 1.274 ± 0.712 | 0.769 ± 0.497 |
Positron emission tomography - computed tomography (ET-CT), CT, or magnetic resonance imaging (MRI) scans of all anatomic regions involved with the disease were performed to assess tumor response using the Response Evaluation Criteria in Solid Tumors, Version 1.1. (RECIST v1.1). Bone metastases were assessed by bone scintigraphy (bone scan). Tumor measurements and evaluation of tumor response were performed at baseline and within the last 7 days of Cycle 2. Thereafter, if subjects continued regorafenib treatment, tumor assessments were performed after every third cycle and at the end-of-treatment (EOT) visit. In addition, outcome of "Assessment of Bone Metastases by Scintigraphy if Applicable (Bone Scan)" was registered, the results of which has been reported as tumor response in this outcome as well.
| participants | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Complete response (CR) | 0 | 0 |
| Partial response (PR) | 0 | 0 |
| Stable disease (SD) | 10 | 5 |
| Non CR/Non PD | 0 | 0 |
| Progressive disease (PD) | 5 | 1 |
| Not evaluable | 0 | 0 |
Collected over From start of study treatment until 30 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Impairment | — | 9/18 (50%) | 18/18 (100%) |
| Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | — | 2/6 (33.3%) | 6/6 (100%) |
| Event | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| Chest painGeneral disorders | 0/18 | 1/6 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/18 | 1/6 |
| Small intestinal obstructionGastrointestinal disorders | 2/18 | 0/6 |
| Stress cardiomyopathyCardiac disorders | 1/18 | 0/6 |
| Intestinal obstructionGastrointestinal disorders | 1/18 | 0/6 |
| PancreatitisGastrointestinal disorders | 1/18 | 0/6 |
| DehydrationMetabolism and nutrition disorders | 1/18 | 0/6 |
| HaematuriaRenal and urinary disorders | 1/18 | 0/6 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/18 | 0/6 |
| RashSkin and subcutaneous tissue disorders | 1/18 | 0/6 |
| Event | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Impairment | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment |
|---|---|---|
| NauseaGastrointestinal disorders | 10/18 | 6/6 |
| FatigueGeneral disorders | 13/18 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 8/18 | 4/6 |
| VomitingGastrointestinal disorders | 6/18 | 4/6 |
| HypertensionVascular disorders | 8/18 | 4/6 |
| Decreased appetiteMetabolism and nutrition disorders | 11/18 | 3/6 |
| HeadacheNervous system disorders | 10/18 | 2/6 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 10/18 | 3/6 |
| Abdominal painGastrointestinal disorders | 5/18 | 3/6 |
| CheilitisGastrointestinal disorders | 1/18 | 3/6 |
| Age, Continuous(years) | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment | Total |
|---|---|---|---|
| Mean | 62.0 ± 9.6 | 64.2 ± 6.9 | 62.5 ± 8.9 |
| Gender(Participants) | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment | Total |
|---|---|---|---|
| Female | 9 | 4 | 13 |
| Male | 9 | 2 | 11 |
The record gives a start of Jun 2013, a primary completion of Jul 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib